Long-term Efficacy and Safety of Sodium Oxybate in Treating Alcohol Use Disorder: A Systematic Review and Meta-Analysis. [PDF]
Curr NeuropharmacolBackground Worldwide, three million deaths each year are reported due to the harmful use of alcohol. To date, only a few drugs have been approved for the treatment of Alcohol Use Disorder (AUD).
Biso L +5 more
europepmc +2 more sources
Narcolepsy 2025 (with an Australasian perspective)
Internal Medicine Journal, Volume 55, Issue 11, Page 1805-1813, November 2025.Abstract Narcolepsy is a disorder of central hypersomnolence, which, while uncommon, can carry profound implications for affected individuals. Despite this, it remains under‐recognised within the medical community and presents frequent diagnostic and treatment challenges in the Australasian setting.
Amelia Lin +3 more
wiley +1 more source
GHB’s Path to Legitimacy: An Administrative and Legislative History of Xyrem [PDF]
, 2012 This paper traces the path of a chemical compound (gamma-hydroxybutyrate, or GHB) from its status as an abused street drug to that of a legitimate, life-altering prescription treatment for a debilitating condition.
Neuman, Ariel
core
Neuroendocrinology meets addiction: Emerging pharmacotherapies on the horizon
Journal of Internal Medicine, Volume 298, Issue 5, Page 392-423, November 2025.Abstract Alcohol and other substance use disorders (ASUDs) are prevalent and major contributors to global morbidity and mortality. Their impact extends beyond the individual, imposing significant burdens on families, communities, healthcare systems, and society at large.
Anna Loften +3 more
wiley +1 more source
Misdiagnosis of narcolepsy [PDF]
, 2016 BACKGROUND: Narcolepsy is a chronic primary sleep disorder, characterized by excessive daytime sleepiness and sleep dysfunction with or without cataplexy.
American Academy of Sleep Medicine +19 more
core +3 more sources
Efficacy and Safety of Sodium Oxybate in Isolated Focal Laryngeal Dystonia: A Phase IIb Double-Blind Placebo-Controlled Cross-Over Randomized Clinical Trial. [PDF]
Ann NeurolTo examine the efficacy and safety of sodium oxybate versus placebo in a phase IIb randomized double‐blind placebo‐controlled 2‐period cross‐over clinical trial in patients with isolated laryngeal dystonia (LD).
Simonyan K +7 more
europepmc +2 more sources
Brain and Behavior, Volume 15, Issue 10, October 2025.Orexin deficiency drives narcolepsy Type 1, leading to excessive daytime sleepiness, cataplexy, and REM intrusions. This review highlights recent advances (2023–2025) in molecular mechanisms, diagnostics, and emerging orexin‐targeted therapies with the potential for disease modification.
Rameesha Rauf +9 more
wiley +1 more source
Patients' perspective of the effectiveness and acceptability of pharmacological and non-pharmacological treatments of fibromyalgia. [PDF]
, 2018 Background and aims Fibromyalgia is a complex condition characterised by widespread pain, sleep disturbance, fatigue and cognitive impairment, with a global mean prevalence estimated at 2.7%.
Ashe, Simon +5 more
core +1 more source
Improvement in sleep latency with extended-release once-nightly sodium oxybate for the treatment of adults with narcolepsy: Analysis from the phase 3 REST-ON clinical trial. [PDF]
Sleep Med XBackground In the REST-ON clinical trial (NCT02720744), mean sleep latency on the Maintenance of Wakefulness Test (MWT) was significantly improved with extended-release once-nightly sodium oxybate (ON-SXB) vs placebo (P < 0.001) in participants with ...
Thorpy MJ +6 more
europepmc +2 more sources
The Space–Time Organisation of Sleep Slow Oscillations as Potential Biomarker for Hypersomnolence
Journal of Sleep Research, Volume 34, Issue 5, October 2025.ABSTRACT Research suggests that the spatial profile of slow wave activity (SWA) could be altered in hypersomnolence. Slow oscillations (SOs; 0.5–1.5 Hz), single waveform events contributing to SWA, can be labelled as Global, Frontal, or Local depending on their presentation on the scalp.
Mahmoud Alipour +5 more
wiley +1 more source